The authors report the results of bismuth blood levels in 41 patients treated by oral route with bismuth salts used in gastro-enterology according to the Bensaude rule (10 to 20 g/day, 20 days/month). Median bismuth blood level during the period of treatment amounts to 13 microgram/l. It decreases to 7 microgram/l during the period of therapeutic withdrawal. In patients with bismuth encephalopathies (63 cases recorded in the literature) median values range from 680 to 700 microgram/l. The authors recommend the determination of bismuth blood levels as a monitoring method in bismuth treatment and propose the following values:--normal level during treatment : less than 50 microgram/l (in Bi metal);--alarm level : 50 to 100 microgram/l : (patients to be monitored);--toxicity level less than 100 microgram/l : (treatment to be interrupted).
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
In vitro and in vivo study of Fr and Bi progeny release from the Ac-labelled TiO nanoparticles.
Nucl Med Biol
November 2024
Joint Research Centre, European Commission, Karlsruhe, Germany.
Background: Targeted alpha therapy (TAT) is an effective option for cancer treatment. To maximize its efficacy and minimize side effects, carriers must deliver radionuclides to target tissues. Most of the nuclides used in TAT decay via the alpha cascade, producing several radioactive daughter nuclei with sufficient energy to escape from the original carrier.
View Article and Find Full Text PDFApplication of three-dimensional visualization technology in early surgical repair of bile duct injury during laparoscopic cholecystectomy.
BMC Surg
September 2024
The Third Clinical Medical College of Ningxia Medical University, Yinchuan, 750002, China.
Objective: This study aimed to explore the application value of three-dimensional (3D) visualization technology in the early surgical repair of bile duct injury during laparoscopic cholecystectomy (LC).
Methods: A retrospective analysis was conducted on the clinical data of 15 patients who underwent early surgical repair of bile duct injury during LC with the assistance of 3D visualization technology at the Hepatobiliary Surgery Department of Ningxia Hui Autonomous Region People's Hospital from January 2019 to December 2022. Postoperative efficacy and long-term follow-up outcomes were summarized.
Evaluation of efficacy and safety of LRa05 in the eradication of : a randomized, double-blind, placebo-controlled trial.
Front Immunol
September 2024
Department of Gastroenterology, Jinshan Hospital, Fudan University, Shanghai, China.
Aim: This study aims to evaluate the efficacy of LRa05 supplementation in enhancing () eradication rate and alleviating the gastrointestinal side effects associated with bismuth quadruple therapy.
Methods: -positive patients were randomized to receive levofloxacin-based bismuth quadruple therapy combined either probiotic LRa05 or a placebo for two weeks, followed by LRa05 (1 × 10 CFU) or maltodextrin for the next two weeks. infection was detected by C breath test pre- and post-treatment.
Cell-free bilayer functionalized scaffold for osteochondral tissue engineering.
J Biosci Bioeng
November 2024
Department of Stem Cells and Regenerative Medicine, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran. Electronic address:
Osteochondral tissue engineering using layered scaffolds is a promising approach for treating osteochondral defects as an alternative to microfracture procedure, autologous chondrocyte implantation, and cartilage-bone grafting. The team previously investigated the chondrogenesis of mesenchymal stem cells (MSCs) on a polycaprolactone (PCL)/acetylated hyaluronic acid scaffold. The present study first focused on fabricating a novel osteoconductive scaffold utilizing bismuth-nanohydroxyapatite/reduced graphene oxide (Bi-nHAp/rGO) nanocomposite and electrospun PCL.
View Article and Find Full Text PDFTotal laparoscopic radical resection of hilar cholangiocarcinoma: preliminary experience of a single center.
BMC Surg
August 2024
Department of General Surgery, Affiliated Hospital of Xuzhou Medical University, #99 Huai Xi Road, Jiangsu, Xuzhou, 221002, P. R. China.
Background: The aim of this study was to describe our preliminary experience in the procedure of laparoscopic radical resection of hilar cholangiocarcinoma and to evaluate its feasibility, safety, and clinical efficacy.
Methods: A retrospective analysis was conducted on 44 patients with hilar cholangiocarcinoma who underwent laparoscopic surgery at our hospital from August 2019 to September 2023. Clinical data were collected from these patients, including 13 cases of Bismuth type I, 17 cases of Bismuth type II, 5 cases of Bismuth type IIIa, and 9 cases of Bismuth type IIIb.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!